Work

Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy

Year: 2019

Type: article

Study design: Observational Study

Source: Annals of Oncology

DOI: 10.1093/annonc/mdz255.039

Authors: A. Hepner, M.S. Carlino, D.B. Johnson, C.L. Gérard, S. Lo, L. Pallan, I.D. Silva, O.A. Michielin, G.V. Long, A.M. Menzies

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2978696425

FWCI: 0.211

Cites:

Cited by: 3

Related to: 10